Home > Selected Past Studies

SELECTED PAST STUDIES - All Cancers - Gastric - Colorectal - Pancreas Cancers

Study

Disease

type & number of samples

Specific Requirements

associated data required

GI-1

Colorectal Cancer

FFPE Blocks with Known KRAS Mutation Status and Matched Plasma

Prospective

More than 200 subjects

  • Newly Diagnosed patients with Colorectal Cancer stage IV
  • Blood samples collected before treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • KRAS mutation status

GI-2

Colorectal Cancer

FFPE Blocks with Known MMR Status

Retrospective

More than 70 subjects

  • Known DNA mismatch repair (MMR) status
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-3

Colorectal Cancer

FFPE Blocks

Retrospective

More than 20 subjects

2 tissue samples per patient:

  • One pre- treatment
  • One post-treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

GI-4

Colorectal Cancer

FFPE Blocks

Retrospective

More than 500 subjects

  • Primary tumor
  • Stage IIA or higher
  • Surgery for primary colon cancer with a minimum of three years follow up, not treated with adjuvant chemotherapy
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

GI-5

Colorectal Cancer

FFPE slides

Retrospective

More than 60 subjects

  • FFPE sections (10 slides of 10 μm) and one H&E stained slide
  • Patients who underwent chemotherapy (surgery excluded): 50% responders & 50% non responders
  • Samples collected before treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Radiological data with tumor and metastases sizes before and after/during the treatment

GI-6

Colorectal Cancer

Freshly Resected Tumor Tissue

Prospective

5 subjects

  • Adenocarcinoma
  • Any stage
  • Sample size: 2 g
  • Samples must be received fresh within 48 hour of resection
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-7

Colorectal Cancer and Polyps

Serum

Retrospective

More than 60 subjects:

3 groups:

  • Patients with Colorectal Cancer stage I & II
  • Patients with Adenomatous Polyps
  • Patients with Hyperplastic Polyps
  • Group CRC: Samples collected before any treatment o surgery
  • Group 2 & 3: Samples collected at time of colonoscopy
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-8

Colorectal Cancer

Serum

Prospective

More than 70 subjects

Patients treated with EGFR inhibitors:

  • 50% patients with no adverse events
  • 50% patients with diverse events
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Date of treatment initiation
  • Date and Description of adverse events

GI-9

Rectal Cancer

Serum

Retrospective

More than 100 subjects

  • Locally Advanced Rectal Carcinoma (LARC), Stages II/III
  • Samples collected before treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and a 3 years medical out-come

GI-10

Gastric Cancer

FFPE Blocks and Matched PBMC

Retrospective

More than 50 subjects

  • 2 groups: with or without relapse within 5 years
  • Samples collected at diagnosis, before start of any treatment
  • FFPE blocks must allow to cut at least 50 sections
  • PBMC isolated from 10 mL of blood
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Biomarker status: EGFR, KRAS

GI-11

Gastric Cancer

Frozen Tissue

Retrospective

More than 50 subjects

  • 2 samples per subject (greater than 0.5 gJ Gastric tumor and Normal Adjacent Tumor tissues
  • Age, Gender, Ethnicity
  • Sample collection date
  • Weight, height, BMI

GI-12

Gastric Cancer

Whole Blood

Retrospective

More than 10 subjects

  • Stage III or IV
  • Samples collected from patients not under treatment: collected at time of diagnostic before any treatment
  • Whole blood collected on specific preservative tubes
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-13

Adenocarcinoma of the Esophagogastric Junction

FFPE Blocks

Retrospective

More than 40 subjects

  • Adenocarcinoma of the Esophagogastric Junction
  • Stage IIIB or higher
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-14

Esophagus Carcinoma

FFPE Blocks

Retrospective

More than 160 subjects

2 groups:

  • Adenocarcinomas
  • Squamous Cell Carcinomas
  • Stage III or higher
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

GI-15

Hepatocellular Carcinoma

Tissue Micro-Arrays

Retrospective

More than 180 subjects

  • Patients newly diagnosed and treatment naïve
  • All stages must be provided
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

GI-16

Liver Cancer

FFPE Blocks AND Matched Serum

Retrospective

More than 50 subjects

  • Hepatocellular Carcinoma, Cholangiocarcinoma, metastatic adenocarcinoma or carcinoma…
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-17

Hepatocellular Carcinoma

FFPE Blocks

Retrospective

More than 200 subjects

  • Asian patients only
  • Child Pugh Score < or equal to 7 (one-year survival rate >80%)
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History
  • Child Pugh score

GI-18

Hepatocellular Carcinoma

FFPE Blocks with Matched PBMC

Retrospective

More than 40 subjects

  • 2 groups: with or without relapse within 5 years
  • Samples collected at diagnosis, before start of any treatment
  • FFPE blocks must allow to cut at least 50 sections PBMC isolated from 10 mL of blood
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

GI-19

Hepatocellular Carcinoma

FFPE Slides

Retrospective

More than 20 subjects

  • Asian patients only
  • Primary HCC
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-20

Hepatocellular Carcinoma

FFPE Blocks and Matched Serum

Retrospective

More than 10 subjects

  • Patients with primary Hepatocellular Carcinoma (HCC)
  • Advanced stage/higher grade
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-21

Pancreatic Adenocarcinoma

Frozen Tissue and Matched Plasma

Retrospective

More than 20 subjects

  • Any stage
  • Frozen tissue of primary tumor
  • Specimen collected at time of diagnosis
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • KRAS mutation status

GI-22

Pancreatic Adenocarcinoma

FFPE Blocks and Matched Serum

Retrospective

More than 50 subjects

  • Pancreatic ductal adenocarcinoma
  • Any stage
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-23

Neuroendocrine Pancreatic Cancer

FFPE Blocks

Retrospective

More than 20 subjects

  • Pancreatic neuroendocrine tumor
  • Advanced stages
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-24

Metastatic Pancreatic Cancer

FFPE Blocks

Retrospective

More than 30 subjects

  • Metastatic pancreatic ductal adenocarcinoma
  • Core needle biopsies of pancreatic ductal adenocarcinoma metastasis from liver
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-25

Pancreatic Cancer

Serum

Retrospective

More than 300 subjects

11 Groups:

  • Resected pancreatic adenocarcinoma
  • Locally advanced pancreatic cancer
  • Metastatic pancreatic cancer
  • Recurrent pancreatic cancer
  • Endocrine pancreatic cancer
  • Symptomatic patients with a negative diagnosis of pancreatic cancer
  • Asymptomatic patients who had incidental findings of a pancreatic cancer identified by abdominal imaging discovered during a work-up for a different medical problem
  • Heriditary pancreatic cancer
  • Pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms, or mucinous cystic neoplasms
  • Choledocholithiasis, cholelithiasis
  • Chronic pancreatitis
  • Frozen serum at -80C
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History